Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with ...
MONTREAL — Key genetic mutations secondary to RAS mutations that are common in differentiated thyroid cancer (DTC) strongly correlate with higher risk and more advanced cancers, as well as ...
SALT LAKE CITY—Cells with a mutation in the gene called K-Ras—found in close to 30 percent of all cancers, but mostly those with worst prognosis, such as pancreatic cancer, colon cancer, and lung ...
It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...
RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...
The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...
A research team led by MSK physician-scientist Dr. Piro Lito discovered that certain inhibitors can short-circuit the out-of-control signaling caused by mutations that fuel cancer growth. Each year, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback